BCA
GYRE icon

Berman Capital Advisors’s Gyre Therapeutics GYRE Stock Holding History

Berman Capital Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-107
Closed -$4K – 1956
2021
Q1 		$4K Hold
107
– – ﹤0.01% 1336
2020
Q4 		$5K Hold
107
– – ﹤0.01% 1142
2020
Q3 		$3K Buy
+107
New +$4.19K ﹤0.01% 1195

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Berman Capital Advisors's GYRE Position: Q2 2021 in Review

Berman Capital Advisors sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 107 shares — an estimated $4K sold.

Berman Capital Advisors first reported a position in GYRE in Q3 2020 and held it in 3 quarters. The position peaked at $5K in Q4 2020. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • Berman Capital Advisors reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Berman Capital Advisors sold 107 Gyre Therapeutics shares in Q2 2021, an estimated $4K.
  • Berman Capital Advisors first reported a position in Gyre Therapeutics in Q3 2020 and held it in 3 quarters.
  • Berman Capital Advisors's Gyre Therapeutics position peaked at $5K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on Berman Capital Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.